.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD01_Erenumab.Erenumab .Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD01_Erenumab.Erenumab| name: | Erenumab |
| ATC code: | N02CD01 | route: | subcutaneous |
| n-compartments | 2 |
Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It is approved for the preventive treatment of migraine in adults.
Pharmacokinetic parameters reported in healthy adult subjects following subcutaneous administration.
Vu, T, et al., & Vargas, G (2017). Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharmaceutical research 34(9) 1784–1795. DOI:10.1007/s11095-017-2183-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28593473
Cohen-Barak, O, et al., & Rabinovich-Guilatt, L (2021). Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia : an international journal of headache 41(10) 1065–1074. DOI:10.1177/03331024211007789 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34000848
Jakate, A, et al., & Lipton, RB (2021). Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. Headache 61(4) 642–652. DOI:10.1111/head.14095 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33818780